Niagen Bioscience (NAGE) stock surged 6.39% in after-hours trading on Wednesday, following the release of its impressive first-quarter 2025 financial results and an increased full-year outlook. The company, which specializes in NAD+ precursors and healthy aging solutions, reported significant growth across key financial metrics, surpassing analyst expectations.

The Q1 2025 results revealed a 38% year-over-year increase in total net sales, reaching $30.5 million. This growth was driven by a 24% rise in Tru Niagen® sales to $21.5 million and a remarkable 95% increase in Niagen® ingredient sales to $8.0 million. The company's net income for the quarter stood at $5.1 million, translating to earnings per share of $0.07, a substantial improvement from a net loss in the same period last year. Notably, Niagen Bioscience's quarterly earnings of $0.06 per share beat the analyst consensus estimate of $0.02 by 200%.

Adding to the positive sentiment, Niagen Bioscience raised its full-year 2025 outlook, projecting net sales growth between 20% and 25%, up from the previous estimate of approximately 18%. This increased guidance reflects the company's confidence in sustained market performance and growing consumer trust in its products. The strong Q1 performance, coupled with strategic initiatives such as the recent corporate rebranding and expansion of its NAD+ precursor patent portfolio, has positioned Niagen Bioscience for continued growth in the expanding healthy aging market.